Additional update: Results of ongoing investigator-initiated proof-of-concept trial in United Arab Emirates (UAE) demonstrate further reduction of total parenteral support (PS) (comprised of total parenteral nutrition and supplementary IV fluids) of approximately 37% SAN FRANCISCO, CA, AL / ACCESS Newswire / October 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today provided... Read More

The two programs are being conducted under separate Single-Patient Investigational New Drug (sIND) applications in the United States SAN FRANCISCO, CA / ACCESS Newswire / September 30, 2025 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) is providing the company's novel crofelemer powder for oral solution for use in two expanded access programs, authorized by the U.S. Food... Read More

Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally SAN FRANCISCO, CA / ACCESS Newswire / September 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced that it has received notice from the U.S. Food and Drug... Read More

Potential treatment for patients with breast cancer with metastasis to the brain with crofelemer would augment the significant responder analysis results for crofelemer in the prespecified subgroup of patients with breast cancer from the OnTarget study that were reported at the Multinational Association of Supportive Care in Cancer 2025 Annual Meeting and the 2024 San Antonio Breast Cancer Symposium SAN FRANCISCO, CA /... Read More

SAN FRANCISCO, CA / ACCESS Newswire / September 23, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, September 25, 2025 at the Emerging Growth Conference and virtually on Tuesday, September 30, 2025 at the Lytham Partners Fall 2025 Conference. Participation Instructions for Jaguar's Virtual Presentation at the Emerging... Read More

Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 5, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually at the H.C. Wainwright 27th Annual Global Investment Conference , which takes place September 8-10, 2025. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 27th Annual Global... Read More

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia ® -CA1 , is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the... Read More

Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register As announced , initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating... Read More

As announced , initial proof-of-concept results from the ongoing investigator-initiated trial in Abu Dhabi show crofelemer reduced the required total parenteral nutrition in the first participating MVID patient by up to 27%; abstract describing results accepted for presentation at upcoming North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago SAN FRANCISCO,... Read More

The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately 35% versus net Q1 2025 revenue of approximately $2.2 million and increased approximately 10% versus net Q2 2024 revenue of approximately $2.7 million Mytesi prescription volume increased approximately 6.5% in Q2 2025 over Q1 2025 and Mytesi prescription volume in Q2... Read More

Click here to register Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025 Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor... Read More

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia ® , conditionally approved for CID, to regulatory approval and commercialization for general diarrhea globally Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no... Read More

Magdalena is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESS Newswire / July 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that an access and benefit sharing agreement focused on two cultivated species of the coca plant - Erythroxylum coca and Erythroxylum novogranatense - from Peru has been signed between Peru's... Read More

As recently announced , initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5% The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a... Read More

Strategic decision positions Jaguar to diversify treasury holdings with a long-term digital store of value SAN FRANCISCO, CA / ACCESS Newswire / June 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that its Board of Directors has unanimously authorized the Company to include cryptocurrency as a treasury reserve asset. "Cryptocurrencies continue to gain investor attention and... Read More

Canalevia ® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study Diarrhea is one of the most common reasons owners bring their dog to the... Read More

Company's CEO, board members, other C-suite members, and institutional and accredited investors are participants in the extension of the bridge financing SAN FRANCISCO, CA / ACCESS Newswire / June 24, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of... Read More

Enrollment in company's first-of-its-kind placebo-controlled Phase 2 study to evaluate the efficacy of crofelemer for microvillus inclusion disease (MVID) in pediatric patients has reached approximately 25% As recently announced , initial proof-of-concept results of the ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in patients with intestinal failure due to MVID... Read More

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 17, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Wednesday, June 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar's Virtual Presentation at the Emerging Growth Conference When: Wednesday, June 18, 2025 from 9:40 - 10:10 AM Eastern... Read More

MIAMI, June 17, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 83 r d Emerging Growth Conference on June 17 & 18, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register... Read More

Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general,... Read More

Click here to register Discussion will focus on company's May 2025 meeting with the FDA to review the statistically significant responder analysis results for the subgroup of breast cancer patients in company's recently conducted Phase 3 OnTarget trial The currently estimated US metastatic breast cancer population potentially qualifies as an orphan population, in alignment with company's core focus on orphan diseases Company... Read More

Productive and collaborative discussion on proposed pathway by the company to bring crofelemer to approval for cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies The currently estimated US metastatic breast cancer population would qualify as an orphan population, which aligns with company's core focus on orphan diseases Company plans to promptly pursue... Read More

Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. ( NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion will focus on Jaguar's ongoing efforts to further its orphan disease... Read More

SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company agreed to issue to investors... Read More

As announced , initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment after just 8 days, as patient's... Read More

The combined net Q1 2025 revenue of approximately $2.2 million for prescription and non-prescription products, including license revenue, decreased approximately 6% versus net Q1 2024 revenue of $2.4 million and 37% versus net Q4 2024 revenue of $3.5 million Mytesi prescription volume increased by approximately 1.8% in Q1 2025 over Q1 2024 and decreased by approximately 13.5% in Q1 2025 over Q4 2024 REMINDER: Today Jaguar to... Read More

Click here to register Company plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / May 14, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast tomorrow, Thursday, May 15, 2025, at 4:15 p.m. Eastern to review first-quarter 2025 financials and provide corporate updates.... Read More

Company's Canalevia ® -CA1 (crofelemer delayed-release tablets) prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Pet Cancer Awareness Month, a... Read More

Crofelemer is the only oral drug approved by the FDA's Center for Drug Evaluation and Research under Botanical Guidance Click here to access replay of company's April 30, 2025 investor webcast SAN FRANCISCO, CA / ACCESS Newswire / May 7, 2025 / Jaguar Health, Inc . (NASDAQ:JAGX) (Jaguar) today provided an overview of expected Q2 - Q4 2025 catalysts related to potential follow-on indications for crofelemer, the company's... Read More

Jaguar to host investor webcast today at 8:30 AM Eastern to review the initial results from the proof-of-concept study of crofelemer for MVID and SBS-IF presented April 26 at the Annual ELITE PED-GI Congress ; Click here to register There are no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and... Read More

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support... Read More

The webcast will review the MVID and SBS-IF patient experience, the impact of crofelemer on disease progression and quality of life in MVID and SBS-IF, and possible expedited regulatory pathways for crofelemer for MVID; Click here to register There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support... Read More

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients There are currently no approved drug treatments for MVID, an ultrarare pediatric... Read More

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup Jaguar planning to meet with FDA in Q2 2025 to discuss... Read More

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Napo's core target patient audiences for Gelclair are head and neck cancer patients and bone marrow transplant patients SAN... Read More

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 4, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective April 3, 2025, the Company granted 3,600 restricted stock units (RSUs) to New Employee 1, 3,600 RSUs to New Employee 2, 600 RSUs to New Employee 3, 100 RSUs to New Employee 4, 600 RSUs to New Employee 5, and 600 RSUs to New Employee 6. The RSUs for New Employees 1 and 2... Read More

SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / April 1, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced the closing of its previously announced private placement. Jaguar's president and chief executive officer Lisa Conte, as well as other members of the Company's board of directors and other C-suite and senior executives of Jaguar along with selected institutional and accredited investors... Read More

The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13%... Read More

Canalevia ® -CA1 (crofelemer delayed-release tablets) is the first and only treatment for CID in dogs to receive any type of approval from the FDA In dogs undergoing chemotherapy, as is the case with people undergoing cancer treatment, diarrhea is a highly neglected and unmet medical need SAN FRANCISCO, CA / ACCESS Newswire / March 28, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the... Read More

The statistically significant responder analysis results for Mytesi ® (crofelemer) in the OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium Late-breaker abstract recently submitted to the Multinational Association of Supportive Care in Cancer (MASCC) shows additional significant results for breast cancer... Read More

Click here to register for Jaguar's March 27 virtual presentation at the Emerging Growth Conference Click here to register for Jaguar's March 31 investor webcast Company plans to file its annual report on March 31, 2025 on Form 10-K for the year ended December 31, 2024 SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president... Read More

SAN FRANCISCO, CA / ACCESS Newswire / March 26, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that Jaguar's president and chief executive officer Lisa Conte, three other members of the Company's board of directors, and seven other C-suite and senior executives of Jaguar along with selected institutional and accredited investors (each, an "Investor") entered into securities purchase... Read More

Reverse split approved at March 2025 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on March 24, 2025 SAN FRANCISCO, CA / ACCESS Newswire / March 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an... Read More

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer SAN FRANCISCO, CA / ACCESS Newswire / March... Read More

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease FDA meeting expected in Q2 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer Jaguar has received an indication of interest... Read More

This study, initiated yesterday, is one of five clinical efforts - three proof-of-concept (POC) investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and microvillus inclusion disease (MVID) in the US, EU, and/or Middle East/North Africa regions Availability of first IIT proof-of-concept results potentially in H1 2025 Crofelemer, Jaguar's novel plant-based... Read More

Priority Review Vouchers (PRVs) are transferable and, in past transactions by other companies, have sold for prices up to $350 million 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") and Jaguar family company Napo Pharmaceuticals ("Napo") today announced... Read More

SAN FRANCISCO, CA / ACCESS Newswire / February 13, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Tuesday, February 18, 2025 at the Emerging Growth Conference. Participation Instructions for Jaguar Health's Virtual Presentation at the Emerging Growth Conference When: Tuesday, February 18, 2025 from 3:55 - 4:05 PM Eastern Standard... Read More

Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in late 2025/early 2026 SAN FRANCISCO, CA / ACCESS Newswire / February 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke,... Read More

Trial taking place at Sheikh Khalifa Medical City , a flagship United Arab Emirates hospital and largest teaching medical center in Abu Dhabi Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both SBS-IF and MVID Proof-of-concept (POC) data generated from this study could potentially lead to reimbursed early patient access in... Read More

Gastrointestinal disorders are the most frequently reported adverse effects during clinical trials of GLP-1 agonists; GI adverse events usually develop in 40-70% of treated patients, and have been reported in up to 85% Crofelemer, approved by the FDA under the brand name Mytesi ® for HIV-related diarrhea, has demonstrated a significant benefit in improving gastrointestinal symptoms, including diarrhea, abdominal pain and... Read More

Trial taking place at Sheikh Khalifa Medical City , a flagship tertiary hospital in the United Arab Emirates POC data generated from this study could potentially lead to reimbursed early patient access in certain European countries for crofelemer for MVID Crofelemer, Jaguar's novel plant-based prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3. The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs... Read More

Magdalena to explore coca leaf's possible therapeutic benefit for treatment of potentially ADHD or other neuropsychiatric indications The import was conducted in collaboration with the government of Peru Steven King, Ph.D. of Jaguar to speak about the potential promise of coca-based Botanical Drugs at the February 2025 Wisdom of the Leaf Coca Summit in Peru Magdalena is focused on developing novel, natural prescription... Read More

The study is one of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - of crofelemer for the rare disease indications of MVID and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of first IIT proof-of-concept results potentially in Q1 2025 Crofelemer, Jaguar's novel plant-based prescription... Read More

World Health Organization (WHO) has classified the global resurgence of cholera at the highest internal level for emergencies; 1.3 to 4 million cholera cases and 21,000 to 143,000 cholera-related deaths occur each year worldwide Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted orphan-drug designation by the FDA and the European... Read More

Crofelemer is the subject of five clinical efforts - three proof-of-concept investigator-initiated trials (IIT) and two Phase 2 studies - for the rare disease indications of microvillus inclusion disease (MVID) and/or short bowel syndrome with intestinal failure (SBS-IF) in the US, EU, and/or Middle East/North Africa regions; availability of IIT proof-of-concept results potentially in Q2 2025 Virtual event 11:00 AM to 12:00... Read More

Adult patients with breast cancer are a prespecified subgroup of the recently conducted phase 3 OnTarget trial evaluating crofelemer for prophylaxis of CTD The majority of patients in the OnTarget placebo group on abemaciclib and pertuzumab-based therapies required dose reduction or elimination SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo... Read More

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of CTD SAN FRANCISCO, CA / ACCESSWIRE / December 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced that the data from the recently conducted analysis of the prespecified subgroup of adult patients with breast cancer from the... Read More

The study is one of five clinical efforts - three IIT proof-of-concept studies and two Phase 2 studies - of crofelemer for the rare disease indications of SBS-IF and/or microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder, in the US, EU, and/or Middle East/North Africa (MENA) regions; availability of IIT proof-of-concept results potentially in Q2 2025 Crofelemer, Jaguar's novel plant-based... Read More

Canalevia ® -CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree Crofelemer, the active ingredient in Canalevia CA-1, is the subject of Jaguar's recently conducted Phase 3 OnTarget trial in humans for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / December 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today... Read More

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia ® -CA1 , Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA SAN FRANCISCO, CA... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on December 3, 2024 at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference, and present virtually on December 5, 2024 at the Emerging Growth Conference. Participation Instructions for Jaguar Health's... Read More

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs Canalevia ® -CA1, Jaguar's first-generation antisecretory drug for the treatment of chemotherapy-induced diarrhea in dogs, has received extension of conditional approval by FDA Jaguar is... Read More

Established in Milan, Italy in 2021, Napo Therapeutics is focused on expanding access to crofelemer, Jaguar's novel oral plant-based prescription drug, in Europe for orphan and/or rare diseases SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced that Jaguar family company Napo Therapeutics has been named " Best Pharmaceuticals Innovator of the Year - Europe " by The... Read More

The combined net Q3 2024 revenue of approximately $3.1 million for prescription and non-prescription products, including license revenue, increased approximately 14% versus net Q2 2024 revenue of $2.7 million and 11% versus net Q3 2023 revenue of $2.8 million Jaguar reported significant results in breast cancer patients in its phase 3 OnTarget trial for its cancer supportive care drug crofelemer; results in breast cancer... Read More

Click here to register for investor webcast Company plans to file its Earnings Report on November 13, 2024 on Form 10-Q for the quarter ended September 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Wednesday, November 13, 2024 at 8:30 a.m. Eastern to review third-quarter 2024 financials and provide corporate... Read More

Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / November 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar... Read More

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) A second late-breaking abstract related to the OnTarget trial, based on data from the placebo arm of the study, has also been accepted for a poster presentation at SABCS SAN FRANCISCO, CA / ACCESSWIRE / November 4, 2024 / Jaguar Health, Inc.... Read More

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / October 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the abstracts are now available for two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, that show a benefit in patients with chronic... Read More

Gelclair ® is the company's third commercialized prescription product Oral mucositis, also called "chemo mouth," a painful inflammation of the mouth's mucous membranes, has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Severe mucositis/pharyngitis occurred in 70% of head and neck cancer patients in third-party study SAN FRANCISCO, CA / ACCESSWIRE /... Read More

SAN FRANCISCO, CA / ACCESSWIRE / October 11, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective October 7, 2024, the Company granted 80,000 restricted stock units (RSUs) to New Employee 1 and 15,000 RSUs to each of four other new employees ("New Employees 2-5"). The RSUs for New Employee 1 vest equally over three years, with one-third of the shares vesting each year starting... Read More

Magdalena aiming to submit Investigational New Drug (IND) application in early 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD and schizophrenia, with 1-2 additional IND applications filed in 2025 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Dr. Karen Brunke, Jaguar's EVP of... Read More

SAN FRANCISCO, CA / ACCESSWIRE / October 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a late-breaking abstract evaluating the incidence, severity and management of diarrhea from targeted therapies with or without standard chemotherapy in the cohort of adult patients with breast cancer in the placebo group of the OnTarget phase 3 study recently conducted by Jaguar family company Napo... Read More

Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of cancer therapy-related diarrhea OnTarget results in breast cancer patients have been submitted to a relevant oncology conference SAN FRANCISCO, CA / ACCESSWIRE / October 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the recently completed analysis of the... Read More

Jaguar's commercial focus on cancer supportive care aims to use the best tools and techniques that assess the quality of life of cancer patients and survivors and deliver solutions to address these unmet needs - Commonly used tools and techniques fail to measure what patients are most concerned about Jaguar family company Napo Pharmaceuticals sponsored the "More Than a Diagnosis: A Quality of Life Survey for Individuals with... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference , taking place virtually on Tuesday, October 1, 2024. Company Webcast The webcasted presentation will take place at 1:15pm... Read More

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Up to 40% of all patients treated with chemotherapy develop oral mucositis, and this percentage rises to approximately 90% for patients with head and neck cancers treated with chemotherapy and radiotherapy SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2024 /... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on September 19, 2024 at the MedInvest Biotech & Pharma Investor Conference and participate in one-on-one meetings at the event, which is taking place September 18-19 in New York City. Participation Instructions for Jaguar Health's... Read More

FDA-approved Gelclair ® is company's third commercialized prescription product Susan Krizancic appointed to role of National Sales Director at Jaguar family company Napo Pharmaceuticals SAN FRANCISCO, CA / ACCESSWIRE / September 10, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Susan Krizancic to the role of National Sales Director for Jaguar... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will be presenting virtually, and meeting virtually with investors, at the H.C. Wainwright 26th Annual Global Investment Conference , which takes place September 9-11, 2024. Participation Instructions for Jaguar Health's Presentation at the H.C. Wainwright 26th... Read More

Company's Canalevia ® -CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / September 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") is proud to be celebrating National Service Dog Month , a time devoted to raising awareness and... Read More

Click here to view interview video Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair ® and results from independent, investigator-initiated trials of crofelemer for rare diseases SAN FRANCISCO, CA / ACCESSWIRE / September 4, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that a new Innovators with Jane King video... Read More

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More

Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health, is focused on developing novel prescription psychoactive plant-based medicines for various mental health indications SAN FRANCISCO, CA / ACCESSWIRE / August 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Eduardo Zimmer, Ph.D., a key collaborator with Magdalena Biosciences ("Magdalena"), the joint venture formed by... Read More

New patent issued for core rare disease target indication for crofelemer Napo has approximately 230 patents issued and pending Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected... Read More

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net Q1 2024 revenue of $2.35 million and 2.0% versus net Q2 2023 revenue of $2.67 million Company to complete analysis of full data for first and second 12-week periods of pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) in... Read More

Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 results Click here to register for investor webcast Company plans to file its Earnings Report on August 13, 2024 on Form 10-Q for the quarter ended June 30, 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday,... Read More

In 2022 breast cancer was the most common cancer in women in 157 countries out of 185, and lung cancer is the most common cancer worldwide. 1 Click here to register for webcast. Import permit for crofelemer granted for independent, investigator-initiated proof-of-concept trial in Abu Dhabi of crofelemer in pediatric patients for the rare and orphan disease indications of microvillus inclusion disease (MVID) and short bowel... Read More

Dr. Elisabetsky is also an advisor to Magdalena Biosciences , the joint venture formed by Jaguar and Filament Health focused on identifying the next generation of plant-based first-in-class agents for treatment of mental health conditions As announced , Jaguar recently executed an out-license deal with Magdalena Biosciences for a botanical drug candidate for possible schizophrenia and psychoses indications and for... Read More

It is estimated that 10-15% of people in the United States have IBS SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome (SBS) and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with proof-of-concept results expected... Read More

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23 rd at 8:30 AM Eastern to provide updates on company's cancer... Read More

Webcast on Tuesday, July 23rd at 8:30 AM Eastern will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis; Click here to register for webcast Jaguar expands Make Cancer Less Shitty (MCLS) patient advocacy program to incorporate select group of MCLS... Read More

New patents issued for core rare disease target indications for crofelemer Napo has approximately 200 patents issued and pending Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare CDD, in the US, EU, and Middle East/North Africa regions, with results expected in 2024 and 2025 SAN FRANCISCO, CA /... Read More

JAGX's securities continue to be listed and traded on Nasdaq Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on June 25, 2024 the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that... Read More

Jaguar to report pivotal phase 3 OnTarget trial results for its cancer supportive care drug crofelemer on or before July 23, 2024 Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea and oral mucositis In honor of World Rainforest Day (June... Read More

Investor webcast on or before July 23 will include updates on Jaguar's cancer supportive care portfolio, including participation from Jaguar scientific team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral... Read More

SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 4, 2024, the Company granted 1,111 restricted stock units (RSUs) to one new employee. These RSUs vest over one year starting from this new employee's date of hire. The RSUs for this new employee were granted as an inducement material to this new employee's acceptance of employment... Read More

The drug candidate demonstrates antipsychotic activity and has a mechanism of action distinct from FDA-approved therapies for schizophrenia and other mental conditions that present psychotic symptoms Jaguar to receive percent of milestone payments and increasing royalties upon commercialization into the U.S. schizophrenia market, which is estimated to reach $8.06 billion by 2030 Jaguar to present May 30 at Lytham Partners... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 28, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of a third-party, investigator-initiated study of crofelemer, Napo's novel plant-based prescription drug, show that twice daily oral administration of crofelemer led to a statistically meaningful reduction of abdominal pain and discomfort and improved stool... Read More

Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force Top line results imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea 18 million people in U.S. are living with a cancer diagnosis and more than 2 million people in U.S. are expected to be... Read More

Reverse split approved at April 2024 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on May 23, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company will effect a reverse stock split of its issued and outstanding voting common stock ("Common Stock"), at an exchange ratio... Read More

The combined net Q1 2024 revenue of approximately $2.4 million for prescription and non-prescription products increased approximately 20% versus net Q1 2023 revenue of $2.0 million and increased approximately 4% versus net Q4 2023 revenue of $2.3 million Top line results expected to be imminent for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar planning to... Read More

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today issued a reminder that the company will conduct an investor webcast on Tuesday, May 14, 2024 at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate... Read More

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family companies Napo Pharmaceuticals ("Napo") and Napo Therapeutics have submitted a Clinical Trial Application (CTA) to the Italian and German... Read More

Click here to register for May 14 investor webcast Company plans to file its Earnings Report on May 14, 2024 on Form 10-Q for the quarter ended March 31, 2024 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, May 14, 2024, at 8:30 a.m. Eastern to review first-quarter 2024 financials and provide corporate updates.... Read More

Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved anti-secretory agents to treat canine diarrhea SAN FRANCISCO, CA / ACCESSWIRE / May 6, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has established a new Investigational New Animal Drug (INAD) file with... Read More

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024 SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2024 / Jaguar Health, Inc. (Nasdaq:JAGX) today announced that Jaguar family company Napo... Read More

Jaguar planning to begin commercial launch of FDA-approved Gelclair ® prescription gel for oral mucositis (also called “chemo mouth”) in Q3 2024 Company to feature “ Make Cancer Less Shitty ” patient advocacy program at ONS Congress SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that Jaguar family company Napo Pharmaceuticals ("Napo") is exhibiting at the... Read More

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair ® , a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect SAN FRANCISCO, CA / ACCESSWIRE / April 18, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has appointed biopharmaceutical industry veteran Catherine... Read More

Jaguar planning to begin commercial launch in Q3 2024 for Gelclair ® , the company's third prescription product Oral mucositis, also called "chemo mouth," has emerged as the most significant adverse event in oncology according to a National Comprehensive Cancer Network task force SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed an exclusive... Read More

Company not implementing a reverse split at this time Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 9, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders held on April 9, 2024 (the "Special... Read More

Top line results forthcoming for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on April 5, 2024 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") has... Read More

Dr. Massimo Radaelli's core focus will be on further expanding Jaguar's commercial footprint outside the U.S. Dr. Radaelli was instrumental in facilitating the recent out-license agreement with GEN for crofelemer in Turkey and 8 neighboring countries that entails a $2.0 million investment in Jaguar stock at a premium price SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today... Read More

Net revenue was approximately $9.8 million for the year ended December 31, 2023 versus approximately $12.0 million for the year ended December 31, 2022, a decrease of 18% Net Q4 2023 revenue of approximately $2.3 million decreased 18% versus net Q3 2023 revenue of $2.8 million and decreased approximately 30% versus net Q4 2022 revenue of $3.3 million Top line results expected forthcoming for company's phase 3 OnTarget trial... Read More

Click here to register for April 1 investor webcast Company plans to file its Earnings Report on April 1, 2024 on Form 10-K for the year ended December 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, April 1, 2024 at 8:30 a.m. Eastern Standard Time to review fourth-quarter 2024 financials and provide... Read More

Agreement terms to include payment of double-digit royalties to Jaguar on all Crofelemer products sold in the licensed territory SAN FRANCISCO, CA / ACCESSWIRE / March 20, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it has signed a binding term sheet covering the exclusive license and commercialization agreement ("the Agreement") for Jaguar's novel plant-based, FDA-approved prescription drug... Read More

SAN FRANCISCO, CA / ACCESSWIRE / February 23, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the status of its listing with The Nasdaq Stock Market LLC ("Nasdaq"). "Jaguar requested a hearing to appeal a potential delisting of the Company's securities from Nasdaq, and I'm pleased to report that a hearing has been scheduled, " said Lisa Conte, Jaguar's president and... Read More

Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA By prescription only, Canalevia-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA / ACCESSWIRE / February 15, 2024 / Jaguar Health, Inc.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company is donating a supply of its novel plant-based, FDA-approved prescription drug Mytesi ® to Direct Relief , a Santa Barbara, California-based humanitarian aid organization. Active in all 50 states and more than 80 countries, with a mission to improve the health and lives of people affected by poverty or... Read More

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Crofelemer previously granted Orphan Drug Designation by the FDA and the EMA for both short bowel syndrome and microvillus inclusion disease SAN FRANCISCO, CA / ACCESSWIRE / February 12, 2024 / Jaguar Health (NASDAQ:JAGX) today announced that Jaguar family company Napo Pharmaceuticals (Napo) has submitted an Orphan... Read More

Magdalena aiming to submit Investigational New Drug application in 2024 to the FDA for this next-generation psychoactive prescription drug candidate for potential mental health indications such as ADHD, depression & anxiety SAN FRANCISCO, CA / ACCESSWIRE / January 30, 2024 / Jaguar Health, Inc . (NASDAQ:JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences, Inc. (Magdalena), the... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 29, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present in person on January 31, 2024 at The Microcap Conference in Atlantic City, New Jersey and participate in a fireside chat and host one-on-one meetings with investors at the Lytham Partners 2024 Investor Select Conference taking place virtually on February... Read More

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies providing scientific rationale for the use of crofelemer for prevention and treatment of CTD Studies published in peer-reviewed journals and continuum of datapoints highlight the neglected and growing need for treatment of one of the most common and debilitating side effects of... Read More

SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 4, 2024, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of microvillus inclusion disease - an ultrarare CDD - and short bowel syndrome (SBS) in the US, EU, and Middle East/North Africa regions, with results expected in 2024 SAN FRANCISCO, CA / ACCESSWIRE / January 4, 2024 / Napo Pharmaceuticals... Read More

Stage II completed; comprehensive results expected in Q1 2024; company's planned regulatory pathway for FDA approval remains on track Cancer patients at patient advocacy events voice strong support for company's focus on patient quality of life and the highly neglected need for new therapies for cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / December 11, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / December 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that a Multinational Association of Supportive Care in Cancer (MASCC) webinar titled "GI Toxicities from Cancer Therapies - Prevention and Management," taking place Monday, January 29, 2024 from 11:30 AM to 12:30 PM Eastern Standard Time, was made possible by an unrestricted... Read More

SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the abstract for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound... Read More

Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA Crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / December 4, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar Animal Health tradename for the... Read More

Top line data for Jaguar Health's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy forthcoming SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 21, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the company has not yet been provided with results from the company's GCP (Good Clinical Practice) vendors supporting Napo's pivotal Phase 3 OnTarget trial . The trial is evaluating the company's plant-based prescription drug crofelemer for prophylaxis of diarrhea in adult... Read More

Net revenue increased 5% in Q3 2023 versus Q2 2023 Top line results expected before Thanksgiving for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea REMINDER: Jaguar to host investor webcast Tuesday, November 14th at 8:30 a.m. Eastern regarding Q3 2023 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESSWIRE / November 14,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective November 7, 2023, the Company granted 7,500 restricted stock units (RSUs) to one new employee. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. The RSUs for this new employee were granted as an... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 9, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer," an online, anonymous Napo-supported survey initiative of Advocates for Collaborative Education (ACE) to shed light on the diverse and profound challenges... Read More

SAN FRANCISCO, CA / ACCESSWIRE / November 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on November 8, 2023 the Company received formal notice that the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC has granted Jaguar an additional 180-day grace period, through May 6, 2024, to regain compliance with the $1.00 bid price requirement for continued listing... Read More

Click here to register for November 14 investor webcast Company plans to file its Earnings Report on November 14, 2023 on Form 10-Q for the quarter ended September 30, 2023 REMINDER: Jaguar to host virtual educational webinar on rare intestinal failure diseases with leading gastroenterologists and nutrition experts November 8, 2023 from 1:00 PM to 2:30 PM Eastern; Click here to register for webinar SAN FRANCISCO, CA /... Read More

Click here to register for webinar SAN FRANCISCO, CA / ACCESSWIRE / November 7, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today issued a reminder that the company is hosting a virtual educational webinar with leading gastroenterologists and nutrition experts on intestinal failure associated with the rare diseases short bowel syndrome (SBS) and microvillus inclusion disease (MVID)... Read More

Quadri Pharma will cover 50% of the costs of development activity up to a capped dollar contribution Jaguar to host virtual educational webinar on intestinal failure with leading gastroenterologists and nutrition experts November 8 th from 1:00 PM to 2:30 PM EST; Click here to register for the webinar SAN FRANCISCO, CA / ACCESSWIRE / November 2, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family... Read More

New patent issued for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / November 1, 2023 / Napo Pharmaceuticals (Napo), a... Read More

Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications SAN FRANCISCO, CA / ACCESSWIRE / October 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. (Magdalena), the joint venture recently formed by Jaguar and Filament Health... Read More

Individual and institutional investors as well as advisors, analysts, and members of the financial media are invited to attend Jaguar's real-time interactive presentation SAN FRANCISCO, CA / ACCESSWIRE / October 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting virtually at the Emerging Growth Conference on Wednesday, November 1, 2023 from... Read More

Magdalena Biosciences, a joint venture recently formed by Jaguar Health and Filament Health Corp., is focused on developing novel, natural prescription medicines derived from plants for mental health indications Magdalena launches corporate website SAN FRANCISCO, CA / ACCESSWIRE / October 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Magdalena Biosciences, Inc. , the joint venture recently formed by... Read More

MVID, for which there are no approved drug treatments, is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea Crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for MVID, and the Company's Investigational New Drug application for... Read More

Mytesi ® (crofelemer) is indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy Napo to host educational dinner for nurses about HIV-related diarrhea and Mytesi during conference SAN FRANCISCO, CA / ACCESSWIRE / October 18, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that it will exhibit at the Annual... Read More

Top line results expected in the coming weeks for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that it is exhibiting at the Veterinary Cancer Society (VCS) Annual Conference , which takes place October 12-14, 2023... Read More

Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023... Read More

Lip-syncing and singing contest on social media features opportunity to duet with Grammy Award-winner Jenn Colella and encourages open dialogue about chronic and surprise diarrhea Visit the contest social channels @surprisediarrheacontest on TikTok and/or Instagram to enter contest All entries will support donation to nonprofit organization dedicated to supporting HIV long-term survivors; winners will receive prize money,... Read More

SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2023 / In an effort to shed light on the diverse and profound challenges faced by individuals living with a diagnosis or a history of cancer, Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced they were proud to provide fiscal support for "More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of... Read More

Magdalena Biosciences is focused on developing novel, natural prescription medicines derived from plants for mental health indications Import of coca leaves was authorized by the Peruvian Health Authority SAN FRANCISCO, CA / ACCESSWIRE / September 21, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that... Read More

Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More

New patent issued to Napo Pharmaceuticals, a Jaguar Health family company, for core rare disease target indication for crofelemer Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE... Read More

Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar intends to pursue a Tropical Disease Priority Review Voucher, under FDA's financial incentive program, to develop NP-300 for this indication SAN FRANCISCO, CA / ACCESSWIRE / September 12, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health (NASDAQ:JAGX) (Jaguar) family company, today announced that it has... Read More

Click here to access webcast replay Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with... Read More

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 Dr. Brunke to present at the October 30-November 2, 2023 World Orphan Drug Congress in Barcelona and the November 6-8, 2023 BIO-Europe ®... Read More

Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024 SAN FRANCISCO, CA / ACCESSWIRE / August 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing... Read More

Napo Pharmaceuticals, a Jaguar family company, reported completion August 17 of last patient last visit for its pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of cancer therapy-related diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 28, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's president, founder, and CEO, will present virtually at the Emerging Growth... Read More

Jaguar aims to leverage digital technologies including AI enhancement to help connect with investor communities SAN FRANCISCO, CA / ACCESSWIRE / August 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), a commercial-stage pharmaceuticals company developing first-in-class plant-based gastrointestinal (GI) prescription medicines, today announced it has engaged B2i Digital to execute an innovative digital investor engagement and... Read More

Company on track to report top line data in late October 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 17, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo's pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer... Read More

Jaguar Health family company Napo Pharmaceuticals focuses on essential supportive care and management of neglected toxicities in multiple complicated disease states SAN FRANCISCO, CA / ACCESSWIRE / August 16, 2023 / Napo Pharmaceuticals, Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the results of a Napo-sponsored survey of 15 US neurologists who treat patients with amyotrophic lateral... Read More

Net revenue increased 36% in Q2 2023 versus Q1 2023 Top line results expected late October 2023 for company's phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy-related diarrhea Jaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the EU and Middle East/North Africa... Read More

Click here to register for webcast Company plans to file its Earnings Report on August 14, 2023 on Form 10-Q for the quarter ended June 30, 2023 SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, August 14, 2023 at 8:30 a.m. Eastern Daylight Time to review second-quarter 2023 financials and provide corporate... Read More

Funding for Phase 1, 2, and 3 trials sought to develop NP-300 to increase American preparedness and response time in event of exposure to cholera due to bioterrorism or advancement of cholera into US territories due to global warming Cholera is an acute diarrheal illness caused by infection of the intestine with the bacterium Vibrio cholerae Jaguar to present August 10th at Emerging Growth Conference; Individual and... Read More

MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / August 8, 2023 / Napo Pharmaceuticals Inc. (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the activation by the U.S. Food and Drug Administration (FDA) of the... Read More

A significant proportion of patients undergoing cancer therapy experience diarrhea, which has the potential to cause dehydration and non-adherence to cancer treatment regimens Diarrhea was reported in 95% of neratinib-treated patients in randomized placebo-controlled trial SAN FRANCISCO, CA / ACCESSWIRE / August 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company") announced that the results of an... Read More

SAN FRANCISCO, CA / ACCESSWIRE / August 3, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, is presenting at an invitation-only lunch gathering of the Wall Street Wonders Investment Group in New York City at 1:30 p.m. EDT on Friday August 4, 2023. The Wall Street Wonders Investment Group is comprised of fund managers, money managers, retail brokers, family... Read More

Napo Medical Affairs Team Member, who is an HIV/Mytesi ® (Crofelemer) Patient, to Participate in Educational Panel SAN FRANCISCO, CA / ACCESSWIRE / August 2, 2023 / Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals (Napo) issued a reminder today that it will be participating in Pineapple Healthcare's Butt Stuff Brunch with Doctor Carlton - an educational drag show and food event about sexual health featuring guest... Read More

Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated IND SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2023 / Jaguar Health (NASDAQ:JAGX) ("the Company") today announced the activation by the U.S. Food and Drug Administration (FDA) of a physician-requested Investigational New Drug (IND) application to evaluate crofelemer for treatment of uncontrolled diarrhea... Read More

Activities support sustainable supply of Jaguar's botanical drug crofelemer, the active ingredient in the company's FDA-approved human drug Mytesi ® and FDA conditionally approved animal drug Canalevia ® -CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 27, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"), in honor of World Nature Conservation Day, July 28 th , announced that Jaguar, together with its predecessor companies, and... Read More

Canalevia ® -CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA Crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree, is the active ingredient in Canalevia-CA1 SAN FRANCISCO, CA / ACCESSWIRE / July 26, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX), under its Jaguar... Read More

Napo Medical Affairs Team Member, who is an HIV/Mytesi ® (Crofelemer) Patient, to Participate in Educational Panel SAN FRANCISCO, CA / ACCESSWIRE / July 25, 2023 / Jaguar Health (NASDAQ:JAGX) company Napo Pharmaceuticals (Napo) today announced that it will be participating in Pineapple Healthcare's Butt Stuff Brunch with Doctor Carlton - an educational drag show and food event about sexual health featuring guest speaker... Read More

SAN FRANCISCO, CA / ACCESSWIRE / July 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's 2023 Annual Meeting of Stockholders held on July 7, 2023. Five proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A... Read More

MVID is a life-threatening and ultra-rare autosomal recessive disease that affects newborns and children, leading to intestinal failure, significant morbidity and even death from severe secretory diarrhea SAN FRANCISCO, CA / ACCESSWIRE / June 28, 2023 / Napo Pharmaceuticals Inc., a Jaguar Health, Inc. (NASDAQ:JAGX) company, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and... Read More

SAN FRANCISCO, CA / ACCESSWIRE / June 26, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) announced today that the Take C.H.A.R.G.E. ( C anine H ealth A nd R e G istry E xchange) has joined the Global Initiative for Veterinary Cancer Surveillance - an international network of veterinary cancer registries with a mission to: 1) promote international collaborations in animal cancer surveillance and research; 2) create a consensus on... Read More

Diarrhea is a highly neglected and unmet burden of cancer treatment in both people and dogs; A Jaguar-sponsored Gallup survey found that the incidence of U.S. dogs diagnosed with cancer in 2021 was approximately five times the incidence of cancer diagnosed in people SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company is launching an... Read More

Reminder: Jaguar to Present at MedInvest Oncology Investor Conference Wednesday, June 21, 2023 at 6:00 p.m. EDT. Click Here to Register for Event Reminder: Ladenburg Thalmann to Host Virtual Discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care; Click Here to Register for Event SAN... Read More

Reminder: Ladenburg Thalmann to host virtual discussion June 22, 2023 at 1:00 PM EDT with Jaguar CEO and leading patient advocates on impact of cancer therapy-related diarrhea on patients & importance of the patient voice in supportive care; Click here to register for event Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult... Read More

Click here to register for this virtual event taking place at 1:00 PM Eastern on June 22, 2023 Jaguar recently completed patient enrollment in its ongoing pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy SAN FRANCISCO, CA / ACCESSWIRE / June 14, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that... Read More

First U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, to Join International Consortium of Canine Cancer Registries SAN FRANCISCO, CA / ACCESSWIRE / June 8, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar") today announced that it and the cosponsors of the Take C.H.A.R.G.E Canine Cancer Registry ( C anine H ealth A nd R e G istry E xchange), joined by their canine friends, leading veterinary oncologists, and... Read More

Dr. Radaelli appointed Interim Executive Director of Napo Therapeutics S.p.A., the corporation established by Jaguar Health in Italy in 2021 that focuses on expanding crofelemer access in Europe SAN FRANCISCO, CA / ACCESSWIRE / June 7, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that on April 24, 2023, Massimo Radaelli, PhD, a European pharmaceutical industry leader and entrepreneur with more than 30... Read More

256-patient enrollment target met plus 11% over-enrollment; Primary endpoint based on patient reported outcomes from study expected in October 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 25, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has successfully over-enrolled its global, pivotal, Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in adult... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 24, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Stacey Tinianov, MPH, a Board Certified Patient Advocate, has joined the Company's Scientific Advisory Board (SAB). "We are very pleased that Stacey has joined our SAB," said Pravin Chaturvedi, PhD, Jaguar's Chair of the Scientific Advisory Board and Chief Scientific Officer. "Being a cancer... Read More

Announces Focus on Four Cancers Common to Children & Canines for Upcoming Capitol Hill Briefing, Commitment to Advancing Comparative Oncology According to the National Cancer Institute, Roughly 6 Million New Cancer Diagnoses are Made in Dogs Each Year in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 23, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) announced the one-year anniversary of the Take C.H.A.R.G.E. ( C anine H ealth A nd... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement Award Plan"), which was adopted by Jaguar's Board of Directors effective June 16, 2020, has been replenished with 499,171 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). These 499,171 shares... Read More

Jaguar Animal Health's Canalevia ® -CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA conditional approval and is widely available through prominent pet retailers in the U.S. SAN FRANCISCO, CA / ACCESSWIRE / May 16, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on Thursday, May 18, 2023 Lisa Conte, Jaguar's president, founder, and... Read More

Net revenue decreased in Q1 2023 versus Q1 2022 Net loss improved over the same period Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the Phase 3 OnTarget trial Completed and core near-term milestones: Enrollment completed for Phase 3 OnTarget trial Submission of Investigational New Drug (IND)... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the veterinary market, today announced that Canalevia-CA1 (crofelemer delayed-release tablets), the company's U.S. Food and Drug Administration (FDA) conditionally... Read More

AI technology is expected to help make it faster and easier for Mytesi ® patients to start and stay on the drug SAN FRANCISCO, CA / ACCESSWIRE / May 10, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that the Company has launched an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi (crofelemer), the Company's FDA-approved... Read More

Primary endpoint based on patient reported outcomes from study expected in October 2023 With the completion of the PIPE financing of unregistered shares and 6-month lock up term, Jaguar has agreed, as described below, not to issue additional equity securities before October 22, 2023 - by which point the Company expects to have released top line data for the OnTarget trial SAN FRANCISCO, CA / ACCESSWIRE / May 9, 2023 / Jaguar... Read More

Click here to register for webcast Company plans to file its Earnings Report on May 15, 2023 on Form 10-Q for the quarter ended March 31, 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 8, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Monday, May 15, 2023 at 8:30 a.m. Eastern Daylight Time to review first-quarter 2023 financials and provide corporate updates.... Read More

SAN FRANCISCO, CA / ACCESSWIRE / May 5, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective May 2, 2023, the Company granted 100 restricted stock units (RSUs) to New Employee 1 and 4,000 RSUs to New Employee 2. These RSUs vest equally over three years, with one-third of the shares vesting each year starting from the employee's date of hire. All RSUs described above were... Read More

Proof-of-concept studies of crofelemer in patients with short bowel syndrome (SBS) with intestinal failure or congenital diarrheal disorders planned for 2023 SAN FRANCISCO, CA / ACCESSWIRE / May 1, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Napo Therapeutics, the corporation Jaguar established in Italy in 2021 that focuses on expanding access to the Company's oral botanical drug... Read More

91.67% of respondents to a question asking how they see themselves using the product in the future indicated they plan on increasing use of Canalevia ® -CA1 over time Canalevia-CA1, Jaguar Health's FDA Conditionally Approved drug for chemotherapy-induced diarrhea (CID) in dogs, is the first and only treatment for CID in dogs to receive any type of approval from the FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2023 / Jaguar... Read More

Enrollment expected to complete in mid-Q2 2023 As of March 24, 2023, as previously announced, the Company's cash position was approximately $15.3 million SAN FRANCISCO, CA / ACCESSWIRE / April 11, 2023 / Jaguar Health, Inc. (Nasdaq:JAGX) ("Jaguar" or the "Company") today announced that patient enrollment has surpassed 90% in the Company's pivotal Phase 3 OnTarget clinical trial of crofelemer for prophylaxis of diarrhea in... Read More

SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update regarding the Company's efforts to identify trading abnormalities in Jaguar's publicly traded Common Stock that could be markers of potential illegal naked short selling. "As we announced in February, Jaguar engaged Shareholder Intelligence Services, LLC ( ShareIntel ) to help uncover and... Read More

Canalevia ® -CA1 is the first and only treatment for CID in dogs to receive any type of approval from the FDA In December 2022, FDA increased the maximum number of dogs that can be treated annually with a conditionally approved animal drug from 70,000 to 80,000 SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2023 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") under its Jaguar Animal Health tradename for the... Read More

Prescription product net revenue was approximately $11.9 million for the year ended December 31, 2022 versus approximately $4.3 million for the year ended December 31, 2021, an increase of 178.7%. Prescription product net revenue of approximately $3.3 million in Q4 2022 increased 3.4% over Q3 2022 and increased approximately 57% over prescription product net revenue in Q4 2021. As of March 24, 2023, the filing date of... Read More